Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Placebo Thesis?

<< Previous

Bullboard Posts

Next >>

Comment by Danny1082Manon May 26, 2020 8:29pm

174 Views

Post# 31075793

RE:RE:Placebo Thesis?

I agree. However, not sure they could have just pulled the placebo group from those sites, to be fair and not cherry pick all patients (36%) would be pulled out of T1, thus the request to pool the remaining data with T2 (minus the 12%) from those same sites. So the question left would be....is there enough patients (over 400) to power the SAP to statistical significance

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions